Trial Outcomes & Findings for Intense Therapeutic Ultrasound for the Treatment of Chronic Plantar Fasciitis (NCT NCT03254602)

NCT ID: NCT03254602

Last Updated: 2017-12-07

Results Overview

Patient Reported Pain Reduction meeting or exceeding 25% using the Universal Visual Analog Scale. The Universal Visual Analog Scale is a 10 Point pain scale, where 0 = No Pain, 1 = slight Pain and 10 = the patient's worst imaginable pain. Ratings of 2 to 9 describe pain increases of 10%/Rating. For this measure a reduction of 25% on the Universal Visual Analog Scale is considered meeting the Pain Reduction Criteria. Lower Scale numbers compared to reported baseline ratings equates to pain reduction.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

33 participants

Primary outcome timeframe

At 12 weeks after the first treatment

Results posted on

2017-12-07

Participant Flow

Participant milestones

Participant milestones
Measure
Intense Therapeutic Ultrasound Treatment
Intense Therapeutic Ultrasound treatment applied along the length and width of the proximal Plantar Fascia. 1000 - 5 Joule pulses were applied twice, four weeks apart. Intense Therapeutic Ultrasound Treatment
Overall Study
STARTED
33
Overall Study
COMPLETED
29
Overall Study
NOT COMPLETED
4

Reasons for withdrawal

Reasons for withdrawal
Measure
Intense Therapeutic Ultrasound Treatment
Intense Therapeutic Ultrasound treatment applied along the length and width of the proximal Plantar Fascia. 1000 - 5 Joule pulses were applied twice, four weeks apart. Intense Therapeutic Ultrasound Treatment
Overall Study
Lost to Follow-up
4

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Intense Therapeutic Ultrasound Treatment
n=33 Participants
Intense Therapeutic Ultrasound treatment applied along the length and width of the proximal Plantar Fascia. 1000 - 5 Joule pulses were applied twice, four weeks apart. Intense Therapeutic Ultrasound Treatment
Age, Categorical
<=18 years
0 Participants
n=33 Participants
Age, Categorical
Between 18 and 65 years
30 Participants
n=33 Participants
Age, Categorical
>=65 years
3 Participants
n=33 Participants
Age, Continuous
56 years
n=33 Participants
Sex: Female, Male
Female
13 Participants
n=33 Participants
Sex: Female, Male
Male
20 Participants
n=33 Participants
Region of Enrollment
United States
33 Participants
n=33 Participants
Patients with Chronic Plantar Fasciitis where Standard of Care Therapy failed to Reduce Pain
33 Participants
n=33 Participants

PRIMARY outcome

Timeframe: At 12 weeks after the first treatment

Population: Patients receiving 2 Intense Therapeutic Ultrasound Treatments, beginning 12 Weeks ago.

Patient Reported Pain Reduction meeting or exceeding 25% using the Universal Visual Analog Scale. The Universal Visual Analog Scale is a 10 Point pain scale, where 0 = No Pain, 1 = slight Pain and 10 = the patient's worst imaginable pain. Ratings of 2 to 9 describe pain increases of 10%/Rating. For this measure a reduction of 25% on the Universal Visual Analog Scale is considered meeting the Pain Reduction Criteria. Lower Scale numbers compared to reported baseline ratings equates to pain reduction.

Outcome measures

Outcome measures
Measure
Intense Therapeutic Ultrasound Treatment
n=29 Participants
Intense Therapeutic Ultrasound treatment applied along the length and width of the proximal Plantar Fascia. 1000 - 5 Joule pulses were applied twice, four weeks apart. Intense Therapeutic Ultrasound Treatment
Patient Reported Pain Via the Universal Visual Analog Scale: Pass Criteria = at Least 25% Pain Reduction
86 Percent of Patients meeting criteria

SECONDARY outcome

Timeframe: At 12 Weeks after the first treatment

Population: Patients receiving 2 Intense Therapeutic Ultrasound Treatments - Average % Volume Reduction of Hypoechoic Plantar Fascia Lesions

Diagnostic Ultrasound Changes: Hypoechoic Lesion Volume Reduction following 2 Intense Therapeutic Ultrasound Treatments

Outcome measures

Outcome measures
Measure
Intense Therapeutic Ultrasound Treatment
n=26 Participants
Intense Therapeutic Ultrasound treatment applied along the length and width of the proximal Plantar Fascia. 1000 - 5 Joule pulses were applied twice, four weeks apart. Intense Therapeutic Ultrasound Treatment
Ultrasound Changes
56 percentage of Lesion Size Reduction
Interval 0.0 to 100.0

SECONDARY outcome

Timeframe: At 12 Weeks after the first treatment

Population: Patients receiving 2 Intense Therapeutic Ultrasound treatments beginning 12 weeks ago

Compare percentage of Mean changes in pain via the Patient Reported Universal Visual Analog Scale compared to Mean Patient Reported Baseline Pain Scores and percentage of Mean change of Plantar Fascia Hypoechoic Lesion Volume compared to mean baseline Hypoechoic lesion volume following two Intense Therapeutic Ultrasound Treatments, using Diagnostic Ultrasound Images. For Plantar Fascia Hypoechoic Lesion Volume, each lesion volume was calculated using: (4/3) π x R1 x R2 x R3, where r = Radius of each measurement: Lesion Length(1), width(2) and depth(3)

Outcome measures

Outcome measures
Measure
Intense Therapeutic Ultrasound Treatment
n=26 Participants
Intense Therapeutic Ultrasound treatment applied along the length and width of the proximal Plantar Fascia. 1000 - 5 Joule pulses were applied twice, four weeks apart. Intense Therapeutic Ultrasound Treatment
Percentage of Change of Pain and Hypoechoic Lesion Volume Compared to Baseline
Mean % PF Pain Change
-54 percentage of Change
Interval -100.0 to 100.0
Percentage of Change of Pain and Hypoechoic Lesion Volume Compared to Baseline
Mean % Change in PF Hypoechoic Lesion Volume
-56 percentage of Change
Interval -100.0 to 100.0

Adverse Events

Intense Therapeutic Ultrasound Treatment

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Rich Amodei, RDMS

Guided Therapy Systems

Phone: 480-649-8587

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place